key: cord-0833180-dg2uv296
authors: McMahan, Katherine; Giffin, Victoria; Tostanoski, Lisa H.; Chung, Benjamin; Siamatu, Mazuba; Suthar, Mehul S.; Halfmann, Peter; Kawaoka, Yoshihiro; Piedra-Mora, Cesar; Jain, Neharika; Ducat, Sarah; Kar, Swagata; Andersen, Hanne; Lewis, Mark G.; Martinot, Amanda J.; Barouch, Dan H.
title: Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters
date: 2022-03-17
journal: Med (N Y)
DOI: 10.1016/j.medj.2022.03.004
sha: 9b7b91975724a337ddacb48834e3395ee01af7b0
doc_id: 833180
cord_uid: dg2uv296

Background The SARS-CoV-2 Omicron (B.1.1.529) variant has proven highly transmissible and has outcompeted the Delta variant in many regions of the world. Early reports have also suggested that Omicron may result in less severe clinical disease in humans. Here we show that Omicron is less pathogenic than prior SARS-CoV-2 variants in Syrian golden hamsters. Methods Hamsters were inoculated with either SARS-CoV-2 Omicron or other SARS-CoV-2 variants. Animals were followed for weight loss, and upper and lower respiratory tract tissues were assessed for viral loads and histopathology. Findings Infection of hamsters with the SARS-CoV-2 WA1/2020, Alpha, Beta, or Delta strains led to 4-10% weight loss by day 4 and 10-17% weight loss by day 6. In contrast, infection of hamsters with two different Omicron challenge stocks did not result in any detectable weight loss, even at high challenge doses. Omicron infection led to substantial viral replication in both the upper and lower respiratory tracts but demonstrated lower viral loads in lung parenchyma and reduced pulmonary pathology compared with WA1/2020 infection. Conclusions These data suggest that the SARS-CoV-2 Omicron variant may result in robust upper respiratory tract infection but less severe lower respiratory tract clinical disease compared with prior SARS-CoV-2 variants. Funding Funding for this study was provided by NIH grant CA260476, the Massachusetts Consortium for Pathogen Readiness, the Ragon Institute, and the Musk Foundation.

The highly mutated SARS-CoV-2 Omicron variant has led to rapid global spread, including in individuals who have been fully vaccinated 1 

Africa and the United Kingdom suggest that the severity of clinical disease with Omicron may be lower than for prior variants. It is unclear whether this lower clinical severity is due to the Omicron virus itself or if it reflects population immunity due to prior vaccination and/or infection.

Syrian golden hamsters provide a robust model to study SARS-CoV-2 disease, with reproducible weight loss and pneumonia following SARS-CoV-2 infection 2,3 . We developed two SARS-CoV-2 Omicron challenge stocks and assessed clinical disease, viral loads, and histopathology in hamsters.

We generated two independent SARS-CoV-2 Omicron stocks in VeroE6-TMPRSS2 cells (see Methods). Syrian golden hamsters (N=6/group) were inoculated by the intranasal route with 100 ul virus containing 5x10 4 PFU WA1/2020, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) stocks, essentially as we previously reported 2, 4 . Infected hamsters showed a mean reduction of 4-10% of body weight by day 4 (Fig. 1A) and 10-17% of body weight by day 6 ( Fig. 1B) , while uninfected hamsters which showed a mean increase of 1% body weight 2, 4 . One animal infected with WA1/2020 reached the 20% weight loss criteria for humane euthanization, but the rest of the hamsters recovered their body weights by approximately day 10.

Additional groups of hamsters (N=4/group) were inoculated by the intranasal route with 100 ul of 2.5x10 6 PFU, 2.5x10 5 PFU or 2.5x10 4 PFU of Omicron Stock 1 or 2.5x10 5 PFU, 2.5x10 4 PFU or 2.5x10 3 PFU Stock 2. Hamsters inoculated with Omicron Stock 1 showed a J o u r n a l P r e -p r o o f mean reduction of -1%, -2%, and 1% of body weight by day 4 for these challenge doses, respectively (Fig. 1C) . Hamsters inoculated with Omicron Stock 2 showed a mean reduction of 0%, 0%, and 1% of body weight by day 4 for these challenge doses, respectively (Fig. 1D) .

These data demonstrate that two SARS-CoV-2 Omicron stocks did not lead to clinical weight loss in hamsters, even when inoculated at high doses.

We next assessed tissue viral loads on day 4 following infection of additional groups of hamsters with 5x10 4 PFU WA1/2020 (N=13), Beta (N=11), and Omicron Stock 1 (N=12). We selected Omicron Stock 1 for this experiment because of its higher titer. Levels of E subgenomic RNA (sgRNA) and N genomic RNA (gRNA) were assessed by RT-PCR in lungs and nasal turbinates 5, 6 . In lung tissue, hamsters infected with WA1/2020, Beta, and Omicron had a median of 9.07, 9.55, and 8.33 log sgRNA copies/g tissue. Median levels of lung sgRNA were 0.74 log lower in Omicron-infected hamsters compared with WA1/2020-infected hamsters (P=0.004, two-tailed Mann-Whitney test; Fig. 2A) , and sgRNA levels correlated with TCID50 titers (data not shown). In nasal turbinates, hamsters infected with WA1/2020, Beta, and Omicron had a median of 6.35, 7.34, and 8.25 log sgRNA copies/g tissue. Median levels of nasal turbinate sgRNA were 1.90 log higher in Omicron-infected hamsters compared with WA1/2020-infected hamsters (P=0.05, two-tailed Mann-Whitney test; Fig. 2A) . Similarly, median levels of lung gRNA were 0.84 log lower in Omicron-infected hamsters compared with WA1/2020-infected hamsters (P=0.005, two-tailed Mann-Whitney test; Fig. 2B ), but median levels of nasal turbinate sgRNA were 1.49 log higher in Omicron-infected hamsters (P=0.01, two-tailed Mann-Whitney test; Fig. 2B ). Body weights were reduced in the WA1/2020 and Beta infected animals, as J o u r n a l P r e -p r o o f expected, but not the Omicron infected animals on day 4 (Fig. 2C) . These data suggest that Omicron infection in hamsters leads to lower levels of virus in the lower respiratory tract compared with WA1/2020 infection.

Omicron infected hamsters demonstrated reduced bronchiolar epithelial changes, interstitial inflammation and consolidation, and endothelialitis as compared to WA1/2020 infected hamsters on day 4 following infection ( Fig. 3A- Nasal turbinate pathology was pronounced in Omicron infected animals but did not differ in distribution, severity, or viral positivity as compared to WA1/2020 infected hamsters (Fig. S1 ).

Our data demonstrate that the SARS-CoV-2 Omicron variant infected Syrian golden hamsters but did not result in detectable weight loss, even at doses that were 50 times higher than the doses of WA1/2020, Alpha, Beta, and Delta that led to substantial weight loss. The J o u r n a l P r e -p r o o f consistency of these findings with two independent Omicron challenge stocks suggests the generalizability of these conclusions 7, 8 .

Omicron infection led to robust viral replication in both the upper and lower respiratory tracts, with higher viral loads in nasal turbinates and lower viral loads in lung compared with WA1/2020. Moreover, Omicron led to reduced lung histopathology compared with WA1/2020, suggesting that Omicron infection leads to reduced lower respiratory tract disease in hamsters.

Future studies could compare tissue viral loads of Omicron with Delta and additional variants.

Our findings in hamsters are consistent with emerging reports suggesting that Omicron is highly transmissible but induces less severe clinical pneumonia in humans compared with prior SARS-CoV-2 variants. Future studies could further define the pathogenesis of infection with the SARS-CoV-2 Omicron variant and the mechanisms associated with its reduced pathogenicity.

hamsters is predictive for humans. It is also not known whether weight loss or viral loads in the lower respiratory tract is more predictive of severe clinical disease. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Dan Barouch (dbarouch@bidmc.harvard.edu).

This study did not generate new unique reagents.

• No datasets or codes are associated with the paper.

• Data from this study is available from the Lead Contact upon request.

• Any additional information required to reanalyze the data reported in this work paper is available from the Lead Contact upon request. Yoshihiro Kawaoka, University of Wisconsin). All SARS-CoV-2 stocks were fully sequenced.

All TCID50 and PFU assays were in VeroE6-TMPRSS2 cells. Note that TCID50 titers in VeroE6-TMPRSS2 cells are approximately 100-fold higher than TCID50 titers in VeroE6 cells.

Genomic and subgenomic viral load assays. SARS-CoV-2 N gene genomic RNA (gRNA) and E gene subgenomic RNA (sgRNA) was assessed by reverse transcription polymerase chain reactions (RT-PCR) using primers and probes as previously described. 5, 6, 9 Standards were generated by first synthesizing a gene fragment of the genomic N gene or J o u r n a l P r e -p r o o f subgenomic E gene. 6 The gene fragments were subsequently cloned into a pcDNA3.1+ expression plasmid using restriction site cloning (Integrated DNA Technologies). The inserts were in vitro transcribed to RNA using the AmpliCap-Max T7 High Yield Message Maker Kit (CellScript). Log dilutions of the standard were prepared for RT-PCR assays ranging from 1x10 10 copies to 1x10 -1 copies. Viral loads were quantified from lung tissue as follows; total RNA was extracted on a QIAcube HT instrument using the RNeasy 96 QIAcube HT Kit according to manufacturer's specifications (Qiagen). Standard dilutions and extracted total RNA from samples were reverse transcribed using SuperScript VILO Master Mix (Invitrogen) according to manufacturer's specifications. A Taqman custom gene expression assay (Thermo Fisher Scientific) was designed using the sequences targeting the E gene sgRNA. 6 The sequences for the custom assay were as follows, forward primer, sgLeadCoV2. for 20 seconds, then 45 cycles of 95ºC for 1 second and 60ºC for 20 seconds. Standard curves were used to calculate subgenomic RNA copies and copy number was normalized to the input weight of lung tissue (copies/g); the quantitative assay sensitivity was 100 copies per gram.

Histopathology. Tissues were fixed in freshly prepared 4% paraformaldehyde for J o u r n a l P r e -p r o o f 24 hours, transferred to 70% ethanol, paraffin embedded within 7 to 10 days, and blocks sectioned at 5 µm. Slides were baked for 30 to 60 min at 65 °C and then deparaffinized in xylene and rehydrated through a series of graded ethanol to distilled water. Slides were stained with hematoxylin and eosin. Blinded assessment of tissue pathology was performed by two boarded veterinary pathologist (AJM, CPM). The following six features were evaluated as previously In cases where more than one cross-section was available, all lung lobes were quantified as an individual data point. For SARS-N, Iba-1, MPO, and CD3 IHC positivity, the Indica Labs -Multiplex IHC algorithm (v3.1.4) was used for quantitation. In all instances, manual inspection of all images was performed on each sample to ensure that the annotations were accurate.

Analysis of virologic and body weight data was performed using GraphPad Prism 9.1.2 (GraphPad Software). Comparison of data between groups was performed using two-sided Mann-Whitney tests. P values of less than 0.05 were considered significant. Graphical Abstract was generated using BioRender. suggesting that Omicron infection is less severe than infection with prior variants.

• Omicron infected Syrian golden hamsters did not lose weight.

• Omicron infected hamsters had lower viral loads in lung than other variants.

• Omicron infected hamsters showed less severe lung pathology than other variants.

The SARS-CoV-2 Omicron variant has proven highly transmissible and has outcompeted the 

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern

Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques

Virological assessment of hospitalized patients with COVID-2019

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

The authors acknowledge NIH grant CA260476, the Massachusetts Consortium for Pathogen Readiness, the Ragon Institute, and the Musk Foundation (D.H.B.).

This study was designed by D.H.B. Omicron challenge stocks were prepared by M.S. and Y.K.. 

The authors declare no competing interests.

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science.